These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 25518342

  • 1. [Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
    Akaza H.
    Nihon Rinsho; 2014 Dec; 72(12):2108-15. PubMed ID: 25518342
    [Abstract] [Full Text] [Related]

  • 2. Current management of advanced and castration resistant prostate cancer.
    Gomella LG, Petrylak DP, Shayegan B.
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [Abstract] [Full Text] [Related]

  • 3. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [Abstract] [Full Text] [Related]

  • 4. [New era of the treatment of CRPC in Japan].
    Akaza H.
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):804. PubMed ID: 25131863
    [Abstract] [Full Text] [Related]

  • 5. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
    Anantharaman A, Small EJ.
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
    [Abstract] [Full Text] [Related]

  • 6. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T, Basset V, Audenet F, Lebret T, Branchereau J.
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [Abstract] [Full Text] [Related]

  • 7. Current state of castration-resistant prostate cancer.
    Petrylak DP.
    Am J Manag Care; 2013 Dec; 19(18 Suppl):s358-65. PubMed ID: 24494690
    [Abstract] [Full Text] [Related]

  • 8. Managed care implications in castration-resistant prostate cancer.
    Lew I.
    Am J Manag Care; 2013 Dec; 19(18 Suppl):s376-81. PubMed ID: 24494692
    [Abstract] [Full Text] [Related]

  • 9. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.
    Actas Urol Esp; 2011 Dec; 35(10):565-79. PubMed ID: 21757258
    [Abstract] [Full Text] [Related]

  • 10. Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise.
    Tenuta A, Klotz L, Parker JL.
    BJU Int; 2014 May; 113(5b):E82-9. PubMed ID: 24053150
    [Abstract] [Full Text] [Related]

  • 11. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N.
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [Abstract] [Full Text] [Related]

  • 12. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.
    Sternberg CN, Baskin-Bey ES, Watson M, Worsfold A, Rider A, Tombal B.
    BMC Urol; 2013 Nov 09; 13():58. PubMed ID: 24206580
    [Abstract] [Full Text] [Related]

  • 13. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 09; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 14. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D, De Bono JS.
    Eur J Cancer; 2014 Mar 09; 50(4):753-64. PubMed ID: 24418724
    [Abstract] [Full Text] [Related]

  • 15. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H, Garcia JA.
    Curr Opin Urol; 2012 May 09; 22(3):175-82. PubMed ID: 22472509
    [Abstract] [Full Text] [Related]

  • 16. [Updated treatments of castration-resistant prostate cancer].
    Wei YF, Gu XJ, Zhu QY.
    Zhonghua Nan Ke Xue; 2016 May 09; 22(5):455-61. PubMed ID: 27416673
    [Abstract] [Full Text] [Related]

  • 17. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA, Dzik C, Rathkopf D, Scher HI.
    Oncology (Williston Park); 2014 Aug 09; 28(8):693-9. PubMed ID: 25140626
    [Abstract] [Full Text] [Related]

  • 18. Metabolic and toxicological considerations of newly approved prostate cancer drugs.
    Tsao CK, Liaw B, Yee T, Galsky MD, Oh WK.
    Expert Opin Drug Metab Toxicol; 2013 Jul 09; 9(7):835-46. PubMed ID: 23581700
    [Abstract] [Full Text] [Related]

  • 19. The utility of prostate-specific antigen in the management of advanced prostate cancer.
    Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP.
    BJU Int; 2013 Sep 09; 112(5):548-60. PubMed ID: 23826876
    [Abstract] [Full Text] [Related]

  • 20. [Evaluation and diagnosis for castration resistant prostate cancer: CRPC].
    Kamoto T.
    Nihon Rinsho; 2014 Dec 09; 72(12):2103-7. PubMed ID: 25518341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.